georges, I don't get why there was such a big trial of ipilimumab and nivolumab together. Both ramp up the immune system in a non-specific way. If it does its job you're going to have heaps of collateral. I guess the trial was easy to do with individual approvals already in place.
Much better a Cavatak plus Pembrolizumab combo. Cavatak creates a target for the immune system in the right area, Pembrolizumab unleashes an unrestrained immune system (on its own Pembrolizumab is effective in ~70% of people to some extent, but with side effects).
I guess we are testing Cavatak plus Ipilimumab instead for commercial reasons -- unless there is evidence why this combo works better than C+P. The particular combinations chosen are the only thing that slightly concerns me with Viralytics.
VLA Price at posting:
80.0¢ Sentiment: None Disclosure: Held
